Novel EGFR Targeted Compounds Against Different Types of Cancer
Biological Evaluation of Novel Pyrazolotriazolopyrimidine Derivatives as Candidates of EGFR Inhibitors in Cancer Cells
Versandkostenfrei!
Versandfertig in 1-2 Wochen
36,99 €
inkl. MwSt.
PAYBACK Punkte
18 °P sammeln!
Cancer is one of the most serious diseases and represents a major threat to human health all over the world. Epidermal growth factor receptors (EGFRs) have been shown to be implicated in tumour initiation and progression. Despite the important progress in EGFR inhibitors synthesis, many cancers develop resistance to these drugs. Therefore, more effective EGFR tyrosine kinase inhibitors are required for cancer treatment. This study has been conducted to evaluate the biological activities of a series of novel Pyrazolotriazolopyrimidine derivatives (BA623, BA642, BA645) compounds that have been s...
Cancer is one of the most serious diseases and represents a major threat to human health all over the world. Epidermal growth factor receptors (EGFRs) have been shown to be implicated in tumour initiation and progression. Despite the important progress in EGFR inhibitors synthesis, many cancers develop resistance to these drugs. Therefore, more effective EGFR tyrosine kinase inhibitors are required for cancer treatment. This study has been conducted to evaluate the biological activities of a series of novel Pyrazolotriazolopyrimidine derivatives (BA623, BA642, BA645) compounds that have been synthesized as potential epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in human breast (MCF7 and MDA-MB-231), cervical (HELA) and colorectal (Caco-2) cancer. The study suggests that the tested Pyrazolotriazolopyrimidine derivatives especially BA-623 may hold potent anticancer effects.
Andere Kunden interessierten sich für
